Sanofi Reorganizing US Research Operations

French drugmaker Sanofi said Wednesday that it's reorganizing research operations in the U.S..

French drugmaker Sanofi said Wednesday that it's reorganizing research operations in the U.S..

The sales job cuts, which will start with an offer of voluntary buyouts, are due to generic competition eroding sales of some existing drugs or experimental ones not panning out in testing as hoped.

The research reorganization is part of CEO Chris Viehbacher's long-term plan to restructure early drug testing and later-stage development around hubs in different countries.

Sanofi said in a statement that it will be setting up a hub for early-stage drug research in the Boston area, where it already has sizeable operations. That includes the biotech drugmaker Genzyme that Sanofi bought last year.